We are so pleased to announce that NICE, NHS England and Roche have reached agreement on a Managed Access Agreement (MAA) for Evrysdi (Risdiplam) for children and adults with type 1, 2 and 3 SMA. The purpose of the MAA…
It is becoming more apparent than ever that there is a lack of access to physiotherapists for children and adults in the community that specialise in SMA or have knowledge of and training in the condition.
The powerpoint slide Marion used in the latest episode of Physio with Marion titled Choosing a private physiotherapist for you or your child (In the UK) is now available as a PDF document.
Treatsma website reaches national news in Bhutan.
We are pleased to share with you the initiation of MANATEE, a new global Phase 2/3 clinical study that aims to evaluate the safety and efficacy of GYM329 (RO7204239), an investigational anti-myostatin antibody targeting muscle growth in combination with risdiplam, in Spinal Muscular Atrophy (SMA).
TreatSMA Trustee Andi Thornton speaks with SMA UK Trustee Toby Mildon about mental health, treatments, University and work, health care and much more
New Clinical Study Planned to Evaluate the Potential Benefit of an Investigational Higher Dose of Nusinersen in People with SMA Previously Treated with Evrysdi® (risdiplam)
SMA UK has put out a community survey asking for people’s views on what services and activities they should focus on in the future. You can respond to their survey here https://www.surveymonkey.co.uk/r/SMAUKnext